id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-347048-qqft4yc9	Araten, David J.	Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders	2020-09-12		.txt	text/plain	2161	125	55	CASE REPORTS: Case 1 is a 39-year-old woman with an approximately 20-year history of paroxysmal nocturnal hemoglobinuria (PNH), who had recently been switched from treatment with eculizumab to ravulizumab prior to SARS-CoV-2 infection. Case 2 is a 54-year-old woman with a cadaveric renal transplant for lupus nephritis, complicated by thrombotic microangiopathy, who was maintained on eculizumab, which she started several months before she developed the SARS-CoV-2 infection. CONCLUSIONS: We see no evidence of increased susceptibility to SARS-CoV-2 in these patients on anti-complement therapy, which might actually have accounted for the mild course of infection. We now have the opportunity to report on 3 patients who were on therapeutic anti-complement therapy at the time they became infected with the SARS-CoV-2 virus. The mild cases of SARS-CoV-2 infection in these 3 patients may have been related to anti-complement therapy, as suggested by preclinical models and reports of other patients who have received anti-complement therapy for COVID-19.	./cache/cord-347048-qqft4yc9.txt	./txt/cord-347048-qqft4yc9.txt